Zehong Wan
Overview
Explore the profile of Zehong Wan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cui E, Wan Z, Ke C, Wu C, Wang D, Lei C
Opt Express
. 2022 Dec;
30(24):42944-42955.
PMID: 36523004
Laser direct writing (LDW) is a promising candidate for the fabrication of all-dielectric THz absorbers for its high flexibility and material compatibility. However, multi-step processing or multi-layer materials are required...
2.
Zhou S, Wan Z, Lei Y, Tang B, Tao G, Du P, et al.
Opt Lett
. 2022 Mar;
47(5):1291-1294.
PMID: 35230348
High-efficiency GaN-based green LEDs are of paramount importance to the development of the monolithic integration of multicolor emitters and full-color high-resolution displays. Here, the InGaN quantum well with gradually varying...
3.
Zhao X, Wan Z, Gong L, Tao G, Zhou S
Nanomaterials (Basel)
. 2021 Dec;
11(12).
PMID: 34947580
InGaN-based long-wavelength light-emitting diodes (LEDs) are indispensable components for the next-generation solid-state lighting industry. In this work, we introduce additional InGaN/GaN pre-wells in LED structure and investigate the influence on...
4.
Ding X, Stasi L, Dai X, Long K, Peng C, Zhao B, et al.
Bioorg Med Chem Lett
. 2018 Dec;
29(2):212-215.
PMID: 30522952
We describe the discovery and optimization of 5-substituted-N-pyridazinylbenzamide derivatives as potent and selective LRRK2 inhibitors. Extensive SAR studies led to the identification of compounds 18 and 23, which demonstrated good...
5.
Ding X, Stasi L, Ho M, Zhao B, Wang H, Long K, et al.
Bioorg Med Chem Lett
. 2018 Mar;
28(9):1615-1620.
PMID: 29588215
Inhibition of LRRK2 kinase activity with small molecules has emerged as a potential novel therapeutic treatment for Parkinson's disease. Herein we disclose the discovery of a 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine series as potent...
6.
Liu H, Chen Y, Huang L, Sun X, Fu T, Wu S, et al.
J Pharmacol Exp Ther
. 2018 Mar;
365(2):336-345.
PMID: 29511033
Little is known about the impact of the blood-nerve barrier (BNB) on drug distribution into peripheral nerves. In this study, we examined the peripheral nerve penetration in rats of 11...
7.
Ding X, Dai X, Long K, Peng C, Andreotti D, Bamborough P, et al.
Bioorg Med Chem Lett
. 2017 Aug;
27(17):4034-4038.
PMID: 28774425
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR...
8.
Woolford A, Day P, Beneton V, Berdini V, Coyle J, Dudit Y, et al.
J Med Chem
. 2016 Dec;
59(23):10738-10749.
PMID: 27933945
Lp-PLA has been explored as a target for a number of inflammation associated diseases, including cardiovascular disease and dementia. This article describes the discovery of a new fragment derived chemotype...
9.
Zhang X, Wang J, Wan Z
Org Lett
. 2015 Apr;
17(9):2086-9.
PMID: 25871703
A new reagent trimethylsilyl chlorodifluoroacetate (TCDA) is reported for the introduction of a -CF3 group to arenes and heteroarenes. Compared with current known reagents, TCDA shows very broad scope with...
10.
Huiban M, Tredwell M, Mizuta S, Wan Z, Zhang X, Collier T, et al.
Nat Chem
. 2013 Oct;
5(11):941-4.
PMID: 24153372
Molecules labelled with the unnatural isotope fluorine-18 are used for positron emission tomography. Currently, this molecular imaging technology is not exploited at its full potential because many (18)F-labelled probes are...